CeciliaYsabelArana YiMD

Hematology • Scottsdale, AZ

Hematologic Oncology

Physician

Join to view full profile

Dr. Arana Yi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arana Yi's full profile

Already have an account?

Office
13400 E Shea Blvd
Scottsdale, AZ 85259
Phone+1 480-301-8000

Education & Training

University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia, 2012 - 2013
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2009 - 2012
University at BuffaloResidency, Internal Medicine, 2006 - 2009
Cayetano Heredia UniversityClass of 2000

Certifications & Licensure

NM State Medical License 2013 - 2027
AZ State Medical License 2020 - 2026
PA State Medical License 2009 - 2012
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013-2014

Clinical Trials

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2

Publications & Presentations

PubMed

3 citations
Acquired erythropoietic uroporphyria associated with clonal cytopenia of undetermined significance.
Leah A Swanson, Freyr Johannsson, Silvia Tortorelli, Cecilia Arana Yi, Surbhi Shah
JAAD Case Reports. 2023-02-01
6 citations
Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm.
Charles Gaulin, Katalin Kelemen, Cecilia Arana Yi
Life. 2022-07-28
3 citations
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs.
Ahmad Ghorab, Aref Al-Kali, Michelle Elliot, Naseema Gangat, Hasan Alkhateeb
Blood Cancer Journal. 2022-06-24

Lectures

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018